Introduction: Asthma is a prevalent, chronic disease associated with significant risk to patients and cost to healthcare systems. Accurate estimates of length of stay and recovery are important for patient information, physician prognostication, and management of inpatient beds.
1
Asthma is becoming more common, 2 and was the 28th most common cause of loss of disability adjusted life-years (DALYs) worldwide in 2010 3 with fatality rates of up to 35
per 100 000 asthmatics. Asthma affects around 5.4 million people in the UK (16% of the population) 1, 4 and many of these remain poorly controlled on maximal medical therapy. Asthma is a worldwide threat, leading to deaths worldwide including 3345 asthma deaths reported in US in 2011 5 and around 1000 people per year die of asthma in the UK, 4 representing annual death rates of 1 in 93 000 and 64 000, respectively. It is therefore vital that we better understand the biology underlying exacerbations. The prevalence and potential risk of asthma equate to a large cost to healthcare systems. The UK National Health Service (NHS) spends around £1 billion per year 6, 7 caring for people with asthma, with 80% of this spent on the most severe 20% of patients. There were 65 316 hospital admissions with asthma in the UK in 2011-2012 4 representing a significant burden to the NHS. Length of stay, the duration of a patient's inpatient admission to hospital, is an important metric of clinical care but also of high importance to those planning healthcare resources. Understanding the likely period a patient will require a hospital bed is relevant to the patient in terms of planning discharge but also to those monitoring bed availability and requirements within a pressurized healthcare system. The coagulation system has been strongly implicated in the pathogenesis of asthma 8 with platelet activation, 9,10 platelet dependant eosinophil migration, 11 and a fibrinogenic 12 or fibrinolytic 13 intra-bronchial environment depending on disease severity. Previous work on length of stay of persons with asthma is mostly confined to the pediatric population 14, 15 or critical care units, 16 and therefore cannot be easily applied to adult admissions. A large retrospective cohort analysis of 56 768 admissions 17 predominantly discussed temporal and demographic characteristics but we could not find previous work examining biochemical and physiological influences on length of stay. We conducted a study aiming to assess factors affecting length of stay and time to recovery in people admitted with acute asthma.
| M A TERI ALS AN D M ETH OD S

| Participants
Over a 15-month period we prospectively recruited 18-70 year old participants with asthma diagnosed at least 1 year previously who were admitted to hospital with an acute exacerbation of asthma. Participants were recruited from 2 UK sites (Portsmouth Hospitals NHS Trust (PHT) and Basingstoke and North Hampshire NHS Foundation Trust (BNHFT)) from the Accident and Emergency department, Medical Assessment Unit or wards. Participants were identified by daily computer searches of the above clinical areas (PHT, n 5 122) or by referral to site researchers (BNHFT, n 5 3). Current smokers and exsmokers with a pack year history of 20 or more were excluded due to the impact of smoking on cytokine levels. Other exclusion criteria were significant cardiopulmonary comorbidities, clinically significant neurological, renal, endocrine, gastrointestinal, hepatic, or hematological abnormalities uncontrolled with standard treatment, pregnant women, long-term anticoagulants or bleeding diatheses, alcohol and drug abuse, immunomodulatory therapy, significantly abnormal chest X-ray, or those in interventional research studies. Participants later found to have an acute diagnosis other than an exacerbation of asthma were withdrawn.
| Study design
In this prospective study, participants were assessed on admission for demographic data, medical history and medications, symptoms and observations, blood tests, spirometry (Microlab 3500 (Carefusion, Hampshire, UK) or Vitalograph Alpha Touch (Vitalograph, Buckinghamshire, UK)), and fractional exhaled nitric oxide (NIOX MINO, Aerocrine, Solna, Sweden). Participants remained under the care of their own clinicians. Participants were discharged when they did not require supplemental oxygen, intravenous medication, or nebulized bronchodilators and their peak flow had recovered to at least 75% of their normal. In view of a lack of standardized definition of recovery from acute exacerbation, participants were asked if they felt they had recovered to baseline at 4 weekly intervals after discharge. 
| Blood tests
| Statistical analysis
Statistical analysis was performed and Pearson product moment correlation coefficients were used to look for key demographic, clinical, or biochemical factors affecting length of stay and time to recovery. Further analysis was performed on factors demonstrating significant correlation using linear regression. Univariable and multivariable analyses were performed using a backward selection model with length of stay or time to recovery as the outcome variable. Time to recovery was analyzed using survival analysis giving hazard ratios for recovery as it was expected that not all patients would report recovery within follow-up. Nonlinear relationships were modeled using polynomial terms. Factors that were not correlated with length of stay or time to recovery were not included in regression models. T-tests were used to compare age and length of stay of those who withdrew relative to the remaining sample, and to compare IL-12 concentration in those with and without family history of asthma. Statistical analyses were conducted using Stata v12.1 (StataCorp, TX) and Excel 2010 (Microsoft Corp, WA). Ethics approval was granted by Berkshire Research Ethics Committee (REC) on 12th August 2010 (REC reference 10/H0505/59).
| R ES ULTS
Data were collected on the acute admissions of 125 participants, 94 females and 31 males with a mean age of 40.0 years and a mean length of stay of 3.98 days. Demographics are shown in Table 1 . Two hundred and fourteen participants were screened, 87 participants failed screening and 29 participants were withdrawn prior to completing the study: 20 withdrew through failure to attend follow-up, 1 participant was shown to have pneumonia in addition to an exacerbation of asthma, 1 started on anti-IgE therapy prior to follow-up, 1 admitted to a higher smoking history following enrolment, 1 had another exacerbation prior to follow-up and 5 participants withdrew themselves.
Length of stay was examined using univariable regression analysis (Table 2 ) and significant increases in length of stay were identified with increasing age (P 5 0.003, Figure 1 ), oxygen requirement on admission (P 5 0.009), aspartate transaminase (P 5 0.04, Figure 2 ), participant-reported wheeze (P 5 0.006) and a decrease in APTT ratio (P 5 0.003, Figure 3 ), FEV 1 (P 5 0.005) and FVC (P 5 0.02). Significant correlation was not found for other factors described in the methods section. Aspartate transaminase concentrations were not significantly different between those given antibiotics prior to admission and those without (P 5 0.87). Participants who withdrew were not significantly different from the rest of the population in terms of length of stay (two tailed t test P 5 0.33) but were significantly younger (mean 32.7 vs. 41.9, P 5 0.001).
Possible factors affecting length of stay (P < 0.2) identified with univariable regression were further examined with multivariable regression (Table 3 ) and wheeze symptoms were found to no longer be associated while the most significant association was with a decreased APTT ratio (P5<0.001) as shown in Figure 3 . Length of stay did not vary significantly between groups receiving low molecular weight heparin (LMWH) as inpatient thromboprophylaxis prior to phlebotomy and those not receiving LMWH (P 5 0.44).
Time to recovery was analyzed using survival methods as not all participants recovered. Univariable analysis (Table 4) showed family history of asthma and admission plasma IL-12 concentrations were significantly associated with delayed recovery. A positive family history gave a hazard ratio of 0.49 for recovery at any given time-point (95% CI 0.30-0.80, P 5 0.005). A detectable plasma IL-12 concentration (>1 pg/ mL) gave a hazard ratio of 0.44-0.52 (P 5 0.04). Family history became non-significant in multivariable regression, leaving admission plasma IL-12 concentration as the only consistent predictor of delayed recovery. IL-12 was not significantly different between groups with positive and negative family history (P 5 0.92). Length of stay did not significantly affect time to participant reported recovery.
| D ISCU SSI ON
These results show that activation of the intrinsic clotting pathway as measured by a drop in the APTT correlates with length of stay and may be a useful biochemical addition to standard measures of exacerbation severity. Figure 3 demonstrates that the majority of variation in APTT ratio occurs within the normal range of 0.8-1.2. This is the first time that APTT has been linked to length of stay in asthma, and this may reflect activation of the intrinsic clotting system by activated platelets. It is recognized that platelet activation occurs during exacerbations of asthma, [8] [9] [10] and activated platelets APTT has been shown to be associated with activation of the clotting system. 19 The APTT may therefore be a marker of the severity of the inflammation within the airways, and that a drop in APTT ratio may represent a more severe exacerbation. This said, D-dimer concentration did not correlate with length of stay and this may be because of increased plasminogen activator inhibitor (PAI-1) and thrombin-activatable fibrinolysis inhibitor (TAFI) concentrations that have been demonstrated in severe asthma. 11 Previous work within our group has shown activation of the extrinsic clotting system within the airways of people with severe asthma, 11 mediated by plasma leak and exposed tissue factor and leading to intra-bronchial fibrin formation. Majoor et al. demonstrated airway and systemic pro-coagulant activity in people with asthma following experimental rhinovirus 16 infection, 20 and it is possible that our findings indicate a viral etiology for our participants' exacerbations. Our data show an increase in aspartate transaminase (AST) correlates significantly with an increased length of stay (Figure 2) , and this has previously been recognized. 21 El-Shaboury et al. reported a series of cases in the BMJ in 1964 demonstrating increases in serum transaminase in 40% of persons admitted with acute asthma. This does not seem to have been an effect of myocardial infarction or glucocorticoid therapy. Suggested explanations included hepatic hypoxia, hepatic venous congestion, and cardiac strain secondary to increased pulmonary resistances but work in this area does not appear to have progressed. The variation in length of stay with age is demonstrated in Figure 1 , showing a nadir around age 35, escalating either side of this. This likely reflects comorbidity and clinical caution rather than being a function of severity of asthma in these participants. Our data do not demonstrate association between length of stay and a number of factors that might be expected to be associated. Severity of asthma, as estimated by inhaled corticosteroid dose, was not associated with length of stay (Table 1) , nor was a delay between symptoms onset and attendance.
Survival analysis showed that participants with detectable levels of plasma IL-12 (>1 pg/mL) had a significantly delayed self-reported recovery (P 5 0.04), although this is not corrected for multiple analysis. Univariable regression showed a significant link between family history and time to recovery although this did not remain significant in multivariable analysis despite a lack of correlation between the two factors. The correlation between plasma IL-12 concentration, indicative of a Th1 differentiation stimulus 22 from macrophages, B-cell precursors and dendritic cells, and delayed recovery may be due to reduced corticosteroid responsiveness. 23 The association of plasma IL-12 with delayed recovery would benefit from confirmation in a further cohort as the significance level of the association was borderline.
| Study limitations
This study is the first to look at the effect of biochemical indices including cytokine concentration on length of stay and recovery, linking these currently academic considerations with clinically relevant outcomes. Recruitment was not powered to detect differences in length of stay, so other factors may become significant in a larger cohort. The younger age of participants who withdrew from the study may have introduced an element of bias into the analysis, although their length of stay was similar to the remaining participants. Participants were asked when they first started experiencing symptoms of their exacerbation to determine whether a delay in presentation resulted in a prolonged admission and this was not seen but this data was subject to recall bias. Cytokine measurement was limited to 61 participants due to prioritization of samples for clinical testing and limited opportunity to return to repeat sampling. Several participants were unable to complete spirometry on admission. We do not believe further samples or testing would have changed our results as few other analyses were approaching significance. Current smokers or ex-smokers of 20 or more pack years were excluded from this study in order to avoid confounding 24 The impact of the coagulation system on the interaction between smoking and asthma has not been described.
| Further work
These data could be used to develop a model for estimated length of stay in people with acute asthma. Further work to elucidate the role of the intrinsic clotting pathway in the pathogenesis of asthma and the cause of raised serum transaminases is needed, both for prognostication and elucidation of therapeutic targets.
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